According to an NBC News article, an FDA panel rejected Biogen’s experimental Alzheimer’s drug due to a lack of “strong evidence” it works. The drug is aducanumab, and it has received ample criticism after experts identified “red flags” in the data, which didn’t show any initial benefits.
FDA Panel Rejects New Alzheimer’s Drug
Biogen’s experimental Alzheimer’s drug lacks enough evidence for FDA approval.
Nov 11, 2020
Recommended
Recommended
Researched List: Blister Machines for Life Sciences
Need a blister machine for life sciences packaging? Our curated list features companies serving pharmaceutical, medical device, nutraceutical, and cosmetic industries. Download to access company names, locations, machine specifications, descriptions, and more.
Download Now
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
Downloads
